This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NuVasive Launches Titanium Spine Implant Modulus TLIF-O
by Zacks Equity Research
The launch of Modulus TLIF-O is expected to boost the AMS portfolio of NuVasive (NUVA).
Align (ALGN), Sraumann Cease Talks on iTero Distribution (Revised)
by Zacks Equity Research
The termination of discussion related to Straumann's iTero distribution is a setback for Align Technologies (ALGN), which is currently focusing on expanding its market base for scanners.
LabCorp Diagnostics Shows Robust Growth Amid Price Declines
by Zacks Equity Research
LabCorp's (LH) Diagnostics business sees an organic uptick in terms of both revenues and volumes in spite of further price reductions.
Align (ALGN) Ceases Straumann Distribution Deal, Shares Slip
by Zacks Equity Research
The termination of the Straumann agreement comes as a setback for Align Technologies (ALGN), which is currently focusing on expanding its market base for scanners.
Abbott (ABT) Hits New 52-Week High on Solid Growth Drivers
by Zacks Equity Research
Abbott (ABT) gains from expansion of product portfolio and several regulatory clearances.
Moving Average Crossover Alert: Penumbra
by Zacks Equity Research
Penumbra, Inc. (PEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Here's Why You Should Invest in Teleflex (TFX) Stock Now
by Zacks Equity Research
Teleflex (TFX) benefits from rising investors' confidence, courtesy of the NeoTract acquisition.
Computer Programs and Systems to Offer Microsoft HealthVault
by Zacks Equity Research
Computer Programs and Systems' (CPSI ) move indicates its efforts to strengthen foothold in the healthcare information technology (HCIT) space.
Zimmer Biomet Grows Internationally Despite Pricing Pressure
by Zacks Equity Research
Zimmer Biomet (ZBH) witnesses strength in the EMEA and APAC regions as well as in the Spine & CMF business.
Align (ALGN) Introduces Intraoral Scanner, Aids iTero Uptake
by Zacks Equity Research
The latest development in Align Technology's (ALGN) iTero arm is expected to be a perfect strategic fit for the company as it will help it further grow its patient base for intraoral scanner.
Insulet (PODD) Hits 52-Week High on Solid Growth Prospects
by Zacks Equity Research
Insulet (PODD) gains from steady global expansion as well as rollout of innovative products like Omnipod DASH and Omnipod Horizon automated insulin delivery system.
Here's Why You Should Add Cardiovascular Systems (CSII) Stock
by Zacks Equity Research
Cardiovascular Systems (CSII) gains on high investors' confidence, courtesy of consistent positive results.
Boston Scientific's New Products, Acquisitions Boost Growth
by Zacks Equity Research
Boston Scientific (BSX) is pulling out all the stops to strengthen its core businesses as well as invest in new technologies and the overseas markets.
Boston Scientific (BSX) Announces Vertiflex Acquisition
by Zacks Equity Research
The acquisition is in sync with Boston Scientific's (BSX) strategy of expanding pain management portfolio.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now
by Zacks Equity Research
QIAGEN (QGEN) is enjoying investors' high confidence, courtesy of the QIAstat-Dx system.
Medtronic Delivers Favorable Outcome on Guardian Connect
by Zacks Equity Research
Medtronic's (MDT) data indicates that Guardian Connect will enable patients to better understand glucose trends and increase Time in Range.
Chemed's VITAS Business Strong, Weak Acuity Mix Shifts a Woe
by Zacks Equity Research
Chemed's (CHE) VITAS registers an expanded average daily census.
Integra LifeSciences' Organic Growth Strong on New Products
by Zacks Equity Research
Banking on product unveilings and a better sales force performance, Integra LifeSciences (IART) pins hopes on accelerated organic growth in the second half of 2019.
Tandem Releases Positive Results Of t:slim X2 Pump Studies
by Zacks Equity Research
The results of the studies are a major breakthrough for Tandem (TNDM) in the field of diabetes treatment.
Smith & Nephew (SNN) Buys Brainlab, Braces Robotic Ecosystem
by Zacks Equity Research
The transaction by Smith & Nephew (SNN), besides the business purchase, comprises certain intangible assets and the orthopaedic Brainlab salesforce.
Varian (VAR) Set to Exhibit ProBeam Proton Therapy System
by Zacks Equity Research
Varian's (VAR) ProBeam exhibition is in sync with its strategy to expand reach within the cancer care market.
DexCom and Companion Medical Collaboration to Support CGM
by Zacks Equity Research
The collaboration enables InPen users to display real-time insulin data in Dexcom's (DXCM) CLARITY Diabetes Management Software.
Walgreens' Weak Market Trends a Woe, Strategic Deals a Boon
by Zacks Equity Research
Walgreens Boots (WBA) is diligently trying to redress specific areas of operational weakness and enhancing its managerial skills for a better operating performance.
QIAGEN-DiaSorin Union to Enhance QuantFERON for Lyme Disease
by Zacks Equity Research
QIAGEN (QGEN) expects multi-site clinical validations for this new system during 2020 Lyme disease season.
Here's Why You Should Invest in Quest Diagnostics (DGX) Stock
by Zacks Equity Research
Quest Diagnostics (DGX) is boosting investors' optimism, courtesy of consistent positive results.